Senior Vice President, Corporate Development

Scott Lipman, M.B.A., serves as Senior Vice President, Corporate Development of Avenzo Therapeutics, leading the company’s business development and strategy functions. Scott most recently served on the Executive Team as Chief of Staff at Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in August 2022, and was an integral part of the business development and strategy, and investor relations teams during his tenure.

Prior to Turning Point Therapeutics, Mr. Lipman worked in Healthcare Investment Banking at Goldman Sachs, where he advised management teams on a range of strategic financial matters, executed financings as well as M&A transactions. He also has worked as a management consultant at ZS Associates, advising biopharma clients on a range of strategic issues, including commercial planning, lifecycle planning, and business development and licensing.

Mr. Lipman received his B.S. in Chemical Engineering from the University of California, Los Angeles and his M.B.A. from the Kellogg School of Management at Northwestern University.